Company: ABBV
Filing Date: 2025-02-19
Form Type: 8-K
Source: 0001104659-25-015015
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-02-19
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events.

On February 18, 2025, AbbVie Inc. (“ AbbVie”)
entered into an underwriting agreement (the “ Underwriting Agreement”) with BofA Securities, Inc., J. P. Morgan Securities
LLC, Morgan Stanley & Co. LLC, Barclays Capital Inc. and Mizuho Securities USA LLC, acting for themselves and as representatives of
the several underwriters named in Schedule II therein (collectively, the “ Underwriters”), pursuant to which AbbVie
agreed to issue and sell to the Underwriters $1,250,000,000 in aggregate principal amount of its 4.650% senior notes due 2028 (the “2028
Notes”), $1,000,000,000 in aggregate principal amount of its 4.875% senior notes due 2030 (the “2030 Notes”),
$1,000,000,000 in aggregate principal amount of its 5.2000% senior notes due 2035 (the “2035 Notes”) and $750,000,000
in aggregate principal amount of its 5.600% senior notes due 2055 (the “2055 Notes” and, together with the 2028 Notes,
the 2030 Notes and the 2035 Notes, the “ Notes”).